HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma.

Abstract
Overexpression of the epidermal growth factor receptor can be found in 80 % of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and is associated with shorter survival. In this work, we evaluated the feasibility of adding cetuximab to concurrent cisplatin and radiotherapy (RT) in locoregionally advanced NPC. Twenty-eight patients with locoregionally advanced NPC who received the combination therapy were retrospectively reviewed and short-term efficacy was evaluated. Grade 3-4 oral mucositis occurred in 20 (71.4 %) patients. Grade 3 radiotherapy-related dermatitis occurred in seven patients (25 %). Three patients (14.3 %) had grade 3 and one patient (3.6 %) had grade 4 cetuximab-related acneiform rashes. These grade 3-4 skin and mucosal toxic effects were manageable and reversible. At a median follow-up of 33.4 months (95 % CI 29.2-38.1 months), the 2-year progression-free survival was 89.3 % (95 % CI 76.4-98.1 %). In conclusion, concurrent administration of cetuximab, cisplatin and RT is a feasible strategy against locoregionally advanced NPC. Preliminary survival data compare favorably with historic data and further follow-up is warranted.
AuthorsHui-Xia Feng, Su-Ping Guo, Gui-Rong Li, Wen-Huan Zhong, Liu Chen, Li-Ru Huang, Hui-Ying Qin
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 31 Issue 9 Pg. 170 (Sep 2014) ISSN: 1559-131X [Electronic] United States
PMID25119503 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cetuximab
  • Cisplatin
Topics
  • Adult
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Carcinoma
  • Cetuximab
  • Chemoradiotherapy, Adjuvant (adverse effects)
  • Cisplatin (adverse effects, therapeutic use)
  • Disease-Free Survival
  • Exanthema (chemically induced, pathology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms (drug therapy, epidemiology, radiotherapy)
  • Radiotherapy, Conformal (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: